HLB Pharma Announces 120 Billion Won Rights Offering - Dilution and Financial Risks Highlighted
HLB Pharma's board on May 13, 2026 approved a rights offering of 10,762,332 common shares (estimated price 11,150 won, total ~120 billion won) with subsequent public offering of unsubscribed shares
Proceeds to be used for facility investment (new factory: 55 billion), operating funds (R&D etc.: 50 billion), and debt repayment (15 billion)
Dilution ratio of 32.81% and discount rate of 25% raises concerns over existing shareholder dilution
Q1 2026 consolidated debt ratio: 33.56%, current ratio: 189.59% (above industry average), but low operating margin (1.57%) and cash holdings of 4.3 billion won indicate financial constraints
Key risks: generic drug price cut (to ~45% from H2 2026), FDA uncertainty for Rivoceranib/Camrelizumab (decision by July 2026), high CSO commission burden, administrative sanctions on albumin health food products